Skip to content

Albireo under pressure on elobixibat strikeout in NASH

August 18, 2020

Thinly traded micro cap Albireo Pharma (NASDAQ:ALBO) is down 12% after hours on light volume in reaction to topline results from a Phase 2 clinical trial evaluating constipation med elobixibat for the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

The 47-subject study met the primary endpoint demonstrating a statistically significant change from baseline in LDL-cholesterol (“bad” cholesterol) at week 16 compared to placebo but failed to achieve any of the secondary NASH endpoints thereby failing to show proof-of-concept.

The company will cease development in NASH as a result.

The oral ileal bile acid transporter inhibitor is marketed in Japan under the brand name GOOFICE.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: